Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
456
datasets available to search
ShareScore release 0.9.0
Dataset results
456 results for “mesothelioma”
Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment
<p>Raw data supporting the manuscript</p>
Viral mimicry response is associated with clinical outcome in pleural mesothelioma
<p>Raw data supporting the manuscript</p>
Dataset related to article "Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells"
<p>This record contains data related to article “Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells”</p> <p><span>Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options.</span></p> <p><span>In this study, we demonstrated that the simultaneous exposure to TTFields and doxorubicin or vinorelbine enhanced treatment efficacy in patient-derived PM cells by increasing intracellular drug concentrations. This was achieved by modulating several genes that encode transport proteins, such as the downregulation of P-glycoprotein.</span></p> <p><span>Using specific, sensitive and quantitative analytical techniques, we observed a more than 70% increase in intracellular concentrations of doxorubicin and vinorelbine in samples treated with TTFields, and a greater than 50% increase in drug uptake in cells exposed to TTFields and pemetrexed. This result indicates that the increased drug concentration observed in TTFields treated cells is significant not only for drugs that are P-gp substrates but also suggests that TTFields could potentially affect other efflux pumps. However, the co-exposure to the drug and TTFields was critical to increasing intracellular drug levels, highlighting the necessity of concurrent use with drugs to enhance the antiproliferative effects of treatment.</span></p> <p><span>The <em>in vitro</em> findings were further corroborated by <em>in vivo</em> pharmacokinetic experiments in mice subcutaneously injected with epithelioid PM tumors. Indeed, a 30% increase in intratumor concentrations was observed when vinorelbine was administered with TTFields.</span></p> <p><span>Our findings suggest that TTFields could be a well-tolerated approach for enhancing intratumoral drug levels and potentially achieving a more significant therapeutic impact on PM treatment.</span></p>
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
ClinicalTrials.gov study NCT03175172. IPD Sharing: NO. Countries: 1. Publications: 1.
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
ClinicalTrials.gov study NCT00398138. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
ClinicalTrials.gov study NCT01160458. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
ClinicalTrials.gov study NCT01362790. IPD Sharing: NO. Countries: 1. Publications: 3.
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT02784171. IPD Sharing: NO. Countries: 3. Publications: 2.
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT00459862. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT01675765. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
ClinicalTrials.gov study NCT01265433. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
ClinicalTrials.gov study NCT02860286. IPD Sharing: NO. Countries: 3. Publications: 1.
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
ClinicalTrials.gov study NCT02899299. IPD Sharing: Not stated. Countries: 21. Publications: 4.
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
ClinicalTrials.gov study NCT04840615. IPD Sharing: YES. Countries: 1. Publications: 1.
Nintedanib (BIBF 1120) in Mesothelioma
ClinicalTrials.gov study NCT01907100. IPD Sharing: Not stated. Countries: 27. Publications: 1.
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
ClinicalTrials.gov study NCT02610140. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
ClinicalTrials.gov study NCT00087698. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT02991482. IPD Sharing: NO. Countries: 3. Publications: 7.
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
ClinicalTrials.gov study NCT00309946. IPD Sharing: Not stated. Countries: 1. Publications: 1.
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
ClinicalTrials.gov study NCT00770120. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.